<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772525</url>
  </required_header>
  <id_info>
    <org_study_id>ACT10573</org_study_id>
    <nct_id>NCT00772525</nct_id>
  </id_info>
  <brief_title>Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to evaluate the effect of Nerispirdine (50 mg or 400
      mg) and placebo given orally as a single dose once a week in crossover design on latency of
      Visual Evoked Potentials (VEP) P100 in optic nerves.

      Secondary objectives included evaluation of the effect of Nerispirdine on VEP amplitude and
      other visual parameters including visual acuity and contrast, as well as evaluation of the
      safety and tolerability of Nerispirdine in patients with Multiple Sclerosis (MS).

      Contrast sensitivity and visual acuity examinations (in addition to Optical Coherence
      Tomography [OCT] and VEPs) were needed during the screening period for defining etiologic
      relationships (if non-MS related impairment) and for assessing the effect of treatment of
      age-related eye disease versus the MS-related vision impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The crossover design included 3 treatment periods 1 week apart and 6 treatment sequences.
      Study participation were to be 5 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Evoked Potential (P100) latency</measure>
    <time_frame>pre-dose and post-dose of each treatment intake (3)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pelli-Robson Contrast Sensitivity Score</measure>
    <time_frame>pre-dose and post-dose of each treatment intake (3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Treatment Diabetic Retinopathy Study (EDTRS) visual acuity score</measure>
    <time_frame>pre-dose and post-dose of each treatment intake (3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Evoked Potential (VEP) amplitude</measure>
    <time_frame>pre-dose and post-dose of each treatment intake (3)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Optic Nerve</condition>
  <condition>Neuritis</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo,1 day treatment period 1
50 mg Nerispirdine, 1 day treatment period 2
400 mg Nerispirdine, 1 day treatment period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo,1 day treatment period 1
400 mg Nerispirdine, 1 day treatment period 2
50 mg Nerispirdine, 1 day treatment period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg Nerispirdine, 1 day treatment period 1
placebo, 1 day treatment period 2
400 mg Nerispirdine, 1 day treatment period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg Nerispirdine, 1 day treatment period 1
400 mg Nerispirdine, 1 day treatment period 2
placebo, 1 day treatment period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg Nerispirdine, 1 day treatment period 1
placebo, 1 day treatment period 2
50 mg Nerispirdine, 1 day treatment period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg Nerispirdine, 1 day treatment period 1
50 mg Nerispirdine, 1 day treatment period 2
placebo, 1 day treatment period 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nerispirdine</intervention_name>
    <description>form: tablet
Route: oral</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
    <other_name>HP184</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>form: tablet
Route: oral</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically definite MS (McDonald criteria), which includes patients with
             remitting-relapsing, secondary progressive, progressive-relapsing, or primary
             progressive MS who have had a past history of Optic Neuritis.

        Exclusion Criteria:

          -  Multiple sclerosis exacerbation within 60 days of the Screening Visit and the relapse
             involved the visual fields or visual acuity

          -  No eye with appropriate degree of lesions for this study as defined by criteria based
             on degree of visual acuity deficit, refractive error, VEP P100 latency and average
             retinal nerve fiber layer thickness of as measured by Optical Coherence Tomography
             (OCT)

          -  Any MS-unrelated prior ophthalmological impairment (eg, compressive, ischemic, toxic,
             or nutritional optic neuropathies, Leber's hereditary optic atrophy)

          -  Previously exposed to 3,4-diaminopyridine or 4-aminopyridine

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert SERGOTT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Institute, Thomas Jefferson University, Philadelphia Pennsylvania, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrave Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2008</study_first_submitted>
  <study_first_submitted_qc>October 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <disposition_first_submitted>January 28, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>January 28, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 26, 2016</disposition_first_posted>
  <last_update_submitted>January 28, 2016</last_update_submitted>
  <last_update_submitted_qc>January 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Visual acuity</keyword>
  <keyword>Contrast sensitivity</keyword>
  <keyword>Visual Evoked Potentials</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

